Huntsman Cancer Institute at the University of Utah signed a contract with Mevion Medical Systems for a second MEVION S250i Proton Therapy System, doubling treatment capacity and broadening access to patients with a wide range of cancers, including pediatric, head and neck, and breast cancers.
A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients.
